A global evaluation of patients and therapies must include, together with clinical and instrumental parameters, the measurement of health-related quality of life (HRQL). Assessing the patient's subjective point of view, offers a more comprehensive description of the impact of the disease and its therapy on everyday life (1) . This is of particular relevance in patients suffering from chronic diseases, when the primary goal of treatment is to improve their functioning in daily life and to achieve the highest level of well-being. Quality of life (QoL) is presently recognized as a primary outcome in clinical trials, population studies and public health. Also physicians and researchers are aware that HRQL is a need, rather than a simple option (2) .
While health status is defined by physicians, the impact of a disease on HRQL is assessed by the patient himself by means of validated instruments (3, 4) . Two types of tools are used. Generic questionnaires are applicable to all health conditions, therefore they allow to compare patients suffering from different diseases as well as ill and healthy subjects. Specific questionnaires are restricted to a particular disease, to a selected population (e.g. adults, children and elderly), or to a specific function (e.g. sexuality) or problem (e.g. pain). These tools are more sensitive than the generic ones, but they do not allow comparison between different diseases.
The history of HRQL in the field of respiratory allergy is chronologically brief but the literature is rich, thus testifying the interest in this topic (5) . During the last years, several questionnaires were validated and standardized for measuring HRQL in children, adolescents and adults with rhinitis or asthma (6) (7) (8) (9) (10) (11) . In parallel, clinical trials have documented the impact of allergic diseases and therapy on the HRQL of patients (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) .
Asthmatic patients are bothered by their symptoms (i.e. shortness of breath, wheezing, cough, chest tightness, Introduction: To date we have available specific instruments assessing healthrelated quality of life (HRQL) in rhinoconjunctivitis or in asthma, but not instruments evaluating rhinitis and asthma together, although they often coexist. The aim of our study was to develop and validate a specific quality of life (QoL) questionnaire for adult patients with rhinoconjunctivitis, asthma or both. Materials and methods: A pool of 42 items covering the main symptoms and problems related to respiratory allergy, was generated based on literature review and clinical experience. The items were randomly listed and presented to 148 consecutive outpatients 46 suffering from asthma (age 32.9 ± 14.3 years), 53 suffering from rhinoconjunctivitis (age 32.6 ± 11.5 years) and 49 from asthma and rhinoconjunctivitis (age 35.6 ± 12.2 years). The patients were asked to indicate which item they had directly experienced and for each of them, its importance on a four-point scale (1 ¼ not important; 4 ¼ very important). Twelve items were cancelled from the list, because of low importance or redundance. In the instrument validation phase, 104 patients (42 with rhinoconjunctivitis alone and 62 with asthma and rhinoconjunctivitis) were evaluated with the generic instrument SF-36 and the new questionnaire (RHINASTHMA). Results: RHINASTHMA was able to differentiate patients with rhinitis from those with both rhinitis and asthma. In stable condition, RHINASTHMA showed good reliability. The factor analysis extracted three factors with a good reliability (0.93, 0.87, 0.76). Discussion: RHINASTHMA is the first tool aimed at evaluating HRQL impairment in patients with rhinitis and/or asthma. It provides a short and simple assessment, and has overall psychometric properties. This is of relevance because of the frequent asthma-rhinitis comorbidity. Recent clinical and epidemiologic studies suggested that a strict relationship between rhinitis and asthma exists (22) (23) (24) . Up to 80% of asthmatic patients also have rhinitis, and rhinitic patients frequently have asthma or nonspecific bronchial hyper-responsiveness. These observations suggested the hypothesis of the unity of upper and lower respiratory tract and that a common pathogenic mechanism underlies rhinitis and asthma, but in previous studies asthma and rhinitis have been kept separated in evaluating HRQL. Indeed the assessment of HRQL in patients with respiratory allergy should consider both upper and lower respiratory tract. At present, this could be performed by using simultaneously two different questionnaires, one for rhinitis and one for asthma. This approach has several limits: (a) filling two questionnaires requires much time, (b) many items are the same in the two questionnaires (i.e. limitation in daily life, practical problems, mood, anxiety) and (c) it is not realistic to describe a unique disease separating it in different components.
The aim of our study was to develop and validate a HRQL questionnaire for adult patients suffering from rhinitis and/or asthma. The questionnaire considers asthma and rhinitis as different aspects of the same disease, so that the patient is not asked to attribute specific symptoms or problems to asthma or rhinitis separately. The new instrument takes into account functional, physical and emotional problems experienced by adult patients with respiratory allergy. This questionnaire was intended to be (1) short, simple and userfriendly, (2) psychometrically sound with good validity and reliability, and (3) useful both in research and clinical practice. The new questionnaire has been named RHIN-ASTHMA.
Materials and methods
The development and testing of the new tool required two separate procedures which were carried out in different groups of patients. The methods used for the two steps are described in detail below.
Patients
All adult patients involved in the development and validation of the questionnaire were seen at our Department. They suffered from respiratory allergy, ascertained through the routine diagnostic procedure. In detail, all patients underwent an interview for clinical and family history, clinical visit and skin prick test for the common allergens (a RAST assay was also performed in selected cases). Rhinitis was clinically diagnosed, following international guidelines.
The diagnosis of asthma was made based on clinical history and the results of pulmonary function test. In particular, a reversible bronchial obstruction (FEV1 <80% predicted with at least 12% increase after inhaled salbutamol 400 mcg) or either positive methacholine challenge were required as diagnostic criteria.
RHINASTHMA development procedure
The first task was to identify all those symptoms and problems, which are perceived as relevant and troublesome by patients with rhinoconjunctivitis, asthma or both.
First, a pool of 42 items was generated based on the following sources: (a) recent literature review of the available HRQL questionnaires and symptom score scales for rhinitis and asthma, (b) discussion with expert allergists and pulmonologists and (c) preliminary unstructured interviews to more than 200 adult outpatients with respiratory allergy. The items concerned both the burden of symptoms and the limitations/problems related to rhinoconjunctivitis and asthma. The items were randomly listed and administered to patients who had to indicate which of the 42 items selected they had directly experienced and the importance of each selected item on a four-point scale (1 ¼ not important; 4 ¼ very important). Patients were also asked to indicate other possible aspects on which the allergic disease might impact and whatever they consider worthy to be added or changed in the questionnaire.
This first phase was carried out in a sample of 150 outpatients, consecutively seen at our Department over a 2-month period. We subsequently calculated: (a) the percentage of patients who indicated each item as a consequence of their disease (frequency range: 0-100), (b) the importance (mean value) attributed from the patient to each item indicated as a problem (range: 0-4) and (c) the overall importance score of the item, defined as the product of the frequency and the mean importance divided by 100 (range: 0-4). The result of this first phase generated a 30-item questionnaire where patients had to indicate, on a Likert scale with multiple options (1 ¼ not at all, 5 ¼ very much), how much they were been troubled by each problem. The questionnaire was then administered to a different patientsÕ population for validation.
RHINASTHMA validation procedure
The questionnaire obtained from the first phase was tested and validated, in accordance with current guidelines, through the following steps:
(a) Criterion validity. It refers to the degree to which the test proves to measure what it is supposed to measure. This was tested by comparing RHINASTHMA scores of rhinitic patients and, patients with asthma and rhinitis, with the aim to identify the burden of rhinitis in respiratory allergy. The Mann-Whitney (MW) nonparametric test was used, because of the sample characteristics. (b) Test-restest reliability. It is the ability of a questionnaire to provide the same results when used repeatedly in stable conditions. A randomized group of 31 stable patients were assessed at baseline and after 1 week. Data were analyzed by t-test for paired samples as recommended in statistical literature (25) (c) Construct validity. It refers to the degree to which a test measures the theoretical ideas underpinning a particular topic. Factorial analysis was performed on RHINASTHMA scores; the principal component method with Varimax rotation was adopted. The concordance between SF-36 and RHINASTHMA was evaluated in order to verify the ability of the new instrument to differentiate rhinitic patients and patients with rhinoconjunctivitis and asthma. In fact, SF-36 is a generic tool widely used to assess HRQL in both asthmatic and rhinitic patients. SF-36 scores were compared by using MW test. The P values were estimated by using the Bonferroni correction. (d) Internal reliability. It measures the homogeneity of a scale. It was established calculating Cronbach's a correlation coefficient on the whole test and on factorial scores. Good correlation was assumed to exist if the coefficients were 0.70 or higher. (e) Responsiveness. It refers to the ability of the questionnaire to detect clinically significant within-subject changes. We determined whether the RHINASTHMA is able to detect differences in QoL scores in a group of 27 patients with respiratory allergy (persistent rhinitis and intermittent asthma) evaluated at baseline and after 3 weeks of treatment with cetirizine. RHIN-ASTHMA score were compared by using a nonparametric test (Wilcoxon).
In this testing phase, 120 consecutive outpatients, diagnosed as having respiratory allergy, were asked to fill-in the generated RHINASTHMA questionnaire and the generic questionnaire SF-36.
Results

RHINASTHMA development procedure
Of 150 patients, two declined to participate, therefore 148 preliminary questionnaires were suitable for the analysis. These patients had a mean age of 33.7 ± 12.7 years (age range 16-73); 46 (31.08%) of them suffered from asthma alone, 53 (35.81%) from rhinoconjunctivitis alone and 49 (33.11%) from asthma and rhinoconjunctivitis. No other significant impact of allergy on life aspects were indicated by patients. The demographics of this population is summarized in Table 1 . Based on the patientsÕ answers, 12 of the proposed items were excluded, because of their low importance or redundancy. Table 2 summarizes the results of the first phase.
RHINASTHMA validation procedure
Of 120 patients, six refused to fill-in the questionnaire, two were excluded because of severe visual impairment and eight were excluded for concomitant severe illness that may have had an impact on HRQL. The characteristics of the 104 eligible patients are shown in Table 3 .
(a) Criterion validity. Table 4 lists the RHINASTHMA average scores which was significantly different in the comparison between the two groups (rhinitis vs. asthma and rhinitis). (b) Test-retest reliability. All items showed a good reproducibility. In fact, the Pearson coefficient ranged between 0.70 and 0.92 for 25 items and between 0.61 and 0.69 for the remaining five items. The lowest were the following (need for medical controls, night awakenings, to clear one's throat, difficulty in concentrating on problems, having to carry drugs with them).
(c) Construct validity. The unlimited factor analysis with eigenvalue >1 extracted seven factors; by reducing the factors to three, 52% of variance was explained. Items belonging to each factor are listed in Table 5 . All the SF-36 subscales significantly differentiated the two groups of patients. SF-36 scores of the two groups are shown in Table 6 . (d) Internal reliability. Cronbach's a coefficient indicated highly satisfactory levels of internal consistency reliability. In fact, all a coefficients were higher than 0.07, the minimum recommended level, and more precisely were 0.93, 0.87 and 0.76 for the three factors extracted. Table 7 details the reliability analysis of the three-factor solution. The postulated distinction among problems and symptoms pertaining to rhinitis, asthma or both seems to be confirmed. (e) Responsiveness. Table 8 shows that RHINASTHMA is able to detect the within-subject changes with a good degree of significance.
Discussion
The HRQL measurement has been successfully applied to respiratory allergy, showing that both rhinitis and asthma have a significant impact on patient's life. Nevertheless, in all the available studies rhinitis and asthma has been considered as distinct diseases; in fact, specific questionnaires addressed to one disease or the other have been developed and validated during the last 10 years. Presently, based on the experimental evidence, it is generally believed that rhinitis and asthma represent two aspects of a single disorder of the respiratory tract. This hypothesis is supported by epidemiologic, clinical and pathophysiologic data, most of them suggesting that a common pathogenic mechanism underlies respiratory allergic diseases. For these reasons we attempted to develop and validate a specific HRQL questionnaire, suitable for patients suffering from respiratory allergy, independent of their disease (rhinitis or asthma). The RHINASTHMA questionnaire was generated and tested following procedures well-established and applied to other similar instruments.
The RHINASTHMA seemed to have good psychometric properties and it is capable of differentiating patients with rhinitis from those with both asthma and rhinitis. Its added value stems from its ability in detecting both quantitative and qualitative differences between the impact of rhinitis alone vs the impact of rhinitis and asthma, and in defining the specific role of rhinitis in impairing patientsÕ daily life. The RINH-ASTHMA is the first specific questionnaire aimed at assessing at the same time either rhinitis or asthma impact on daily life. This could have important effects on clinical practice as well as on clinical trials. In fact, there is the need to Ô…ensure that the impairment in QoL attributed to asthma could not result from the concomitant allergic rhinitisÕ (25) . And, on the other hand, because of the minor clinical relevance of rhinitis compared with asthma, ÔSymptoms of allergic rhinits are likely to be neglected, particularly in patients with asthmaÕ (26) , both by physicians and by patients themselves. Therefore, the RHINASTHMA could to be useful in helping the physician in his diagnostic procedures, in his decision-making processes and in properly evaluating the clinical outcomes. Our results, supported by a rigorous statistical analysis, make us confident that it can be a useful and reliable clinical tool to be used in any clinical situation.
